4 Undervalued Pharmaceuticals Stocks for Thursday, November 07
Discover the top 4 undervalued Pharmaceuticals stocks for Thursday, November 07 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Aneeqa Nadeem
Eunice Kim
Eunice Kim
Grace Malone
Eunice Kim
| Share Statistics | AYTU | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $28.9 | $403.8 | 14% |
|
| Shares Out (Mil) | 19.3 | 47.2 | 30% |
|
| Institutional Ownership | 71.2% | 82.0% | 43% |
|
| Float (Mil) | 7.6 | 49.0 | 16% |
|
| Beta | na | 0.68 | na |
|
| Avg Daily Volume (000s) | 710 | 347 | 64% |
|
| Price Change (52-week) |
31.7% | 51.1% | 78% |
|
| Growth | AYTU | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (2.6%) | 6.6% | 12% |
|
| Net Income (5yr) | 24.5% | (1.4%) | 80% |
|
| EPS (5yr) | 55.9% | 15.1% | 95 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.1%) | (15.1%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | ($0.170) | ($0.510) | $0.155 | |
| Month Ago EPS | ($0.135) | ($0.365) | $0.155 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $0.020 | ($0.075) | na | |
| Year/Year Chg | (15.4%) | (55.9%) | (183.8%) | |
| Financials | AYTU | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $59 | $275 | 21% |
|
| Net Income (TTM) (Mil) | ($20) | ($11) | 23% |
|
| EPS (TTM) | ($1.359) | ($0.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | $4 | ($7) | 35% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $9 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | $11 | $373 | 9% |
|
| Valuation | AYTU | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.92 | 2.20 | 25% |
|
| P/E | na | 21.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AYTU | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 63.3% | 69.4% | 76% |
|
| Net Margin | (34.3%) | 3.5% | 13% |
|
| ROA | (17.9%) | (24.6%) | 21% |
|
| ROE | (73.4%) | (24.4%) | 11% |
|
| Liabilities to Assets | 68.2% | 32.0% | 64% |
|
| F-Score | 3 | 3 | 18% |
|
Aytu BioPharma, Inc. did not pass any screens on 11/19/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors